Experimental drug HE3286: positive data, showed dramatic benefit in trial

[Guest guest]

Hollis-Eden Data Positive

TheStreet.com

http://www.thestreet.com/_googlen/newsanalysis/biotech/10325101.html?cm_ven=GOOG\

LEN & cm_cat=FREE & cm_ite=NA

Hollis-Eden Pharmaceuticals presented positive data from an animal trial on

an experimental drug for rheumatoid arthritis.

The new synthetic steroid hormone, HE3286, showed a dramatic benefit in

rodents with collagen-induced arthritis when compared with a placebo,

reducing the severity of the disease. Results from the trial are being

presented at a conference in Italy.

Hollis-Eden will also present data showing how the drug helps to keep the

immune system from attacking the body itself, which is the cause of

autoimmune diseases like rheumatoid arthritis. The drug will be compared to

the effects of treatment with the steroid dexamethasone.

At a previous scientific meeting, the company presented early data showing

that HE3286 improved glucose tolerance in early insulin resistant type 2

diabetes.

" The observed ability, in these preclinical models, of immune-regulating

hormones to have potent anti-inflammatory properties without side effects

such as immune suppression and bone loss commonly associated with

corticosteroids, provides the potential opportunity to use these compounds

in a broad array of inflammatory conditions, " said Hollis, the

company's chairman and CEO.